Med. praxi. 2017;14(4):164-167 | DOI: 10.36290/med.2017.055
Combination therapy of risk factors of atherosclerosis in clinical practise
- 3. interní klinika VFN a 1. LF UK, Praha
Cardiovascular diseases are still the leading cause of morbidity and mortality in developed countries. Only by complex reviewincluding all risk factors of atherosclerosis are we able to optimally reduce the risk of the patient. Combining drug group enablesthe patient to achieve a certain target value, and obtain improve results due to increasingly strict and clear recommendations.With the increasing amount of pharmacological therapy, the patient adherence to physical therapy unfortunately decreases.Fixed combinations are the most perspective solution for patient adherence to a drug therapy. Nowadays, there are not onlyfixed combinations (especially) for a single risk factor, or a group of factors, available on the market, but also new drugs, whichcontain substances that affect multiple risk factors for atherosclerosis.
Keywords: combination therapy, lipid lowering drugs, antihypertensives, risk factors, atherosclerosis
Received: January 26, 2018; Accepted: March 15, 2018; Prepublished online: March 15, 2018; Published: November 1, 2017 Show citation
References
- www.escardio.org/guidelines.
- Soška V, Vaverková H, Vrablík M, et al. Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011, Vnitř Lék 2013; 59(2): 120-126.
Go to PubMed... - Califf RM, Lokhnygina Y, Cannon PC, et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design, American Heart Journal 2010; 159: 705-709.
Go to original source... Go to PubMed... - SPC přípravku Inegy
- SPC přípravku Zoletorv
- Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 People with Type 2 Diabetes Mellitus (the FIELD Study): Randomised Controlled Trial. Lancet 2005; 366(9500): 1849-1861. Go to original source... Go to PubMed...
- The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574. Go to original source... Go to PubMed...
- Scott M, Grundy MD, Vega GL, et al. Effectiveness and Tolerability of Simvastatin plus Fenofibrate for Combined Hyperlipidemia (the SAFARI trial), The American Journal of Cardiology, Volume 98, Issue 3, 1 August 2006: 427-428.
- SPC přípravku Cholib
- Widimský J. Lipertance(R) - první fixní trojkombinace atorvastatinu, perindopril argininu a amlodipinu, Hypertenze & kardiovaskularni prevence 2016; 2: 63-66.
- SPC přípravku Lipertance
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158. Go to original source... Go to PubMed...
- Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patiens with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8(8): 571-581. Go to original source... Go to PubMed...
- Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011; 27(4): 821-833. Go to original source... Go to PubMed...